Addex Therapeutics Ltd

Entity type image
Type: Company
Name: Addex Therapeutics Ltd (Addex Pharmaceuticals SA)
First reported May 21 2013 - Updated May 22 2013 - 5 reports

ADX71441 on track for phase 1 testing, says Addex

Addex Therapeutics says its gamma-aminobutyric acid B (GABA-B) receptor positive allosteric modulator, ADX71441, caused dose dependent changes in growth hormone (GH) plasma concentrations compared to vehicle control in a rodent preclinical model.These ... [Published MoneyAM - May 21 2013]
First reported May 21 2013 - Updated May 21 2013 - 1 reports

Addex Rises on Positive Rodent Experiment Results: Zurich Mover

Addex Therapeutics Ltd. (ADXN), a Swiss biotechnology company, rose to the highest level in two weeks after saying an experimental molecule influenced growth-hormone concentrations in rodents.Addex advanced as much as 3.8 percent to 6.80 Swiss francs ... [Published BusinessWeek - May 21 2013]
First reported May 15 2013 - Updated May 15 2013 - 1 reports

Addex Reports ADX71441 Reduces Alcohol Intake in a Preclinical Model of Chronic Alcohol Dependence

By a News Reporter-Staff News Editor at Clinical Trials Week -- Addex Therapeutics / Addex Reports ADX71441 ReducesAlcohol Intake in a Preclinical Model of ChronicAlcohol Dependence (see also Pre-Trial Research). Processed and transmitted by Thomson Reuters ... [Published HighBeam Research - May 15 2013]
First reported May 01 2013 - Updated May 02 2013 - 1 reports
NXP Semiconductors NV
NXP Semiconductors NV

NXP Acquires Code Red Technologies

Strategic Addition to NXP Microcontroller Business LineNXP Semiconductors N.V. (NASDAQ: NXPI) today announced its acquisition of Code Red Technologies, an embedded software development tools provider, as a strategic addition to its microcontroller business ... [Published NewsBlaze - May 01 2013]
First reported May 01 2013 - Updated May 01 2013 - 1 reports

Addex Therapeutics Announces CFO, to Transition to External Consulting Role

) - Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced that Tim Dyer, Co-Founder and Chief Financial Officer, will transition to an external consulting role on 1 June 2013 ... [Published BioSpace - May 01 2013]
First reported May 01 2013 - Updated May 01 2013 - 1 reports

Study reinforces dipraglurant data, says Addex

StockMarketWire.com - Addex Therapeutics has announced that dipragluant demonstrated dose-dependent mGlu5 receptor occupancy in a non-human primate positron emission tomography (PET) study. PET is a non-invasive nuclear imaging technique used in drug ... [Published Stock Market Wire - May 01 2013]
First reported May 01 2013 - Updated May 01 2013 - 1 reports

Addex Therapeutics receives European patent for dyskinesia drug

3 minutes ago, 2:32am (ET) 05/01/2013 DatamonitorAddex Therapeutics, a developer of allosteric modulation-based drugs, has received a broad composition of matter patent from the European patent office covering dipraglurant and other mGlu5 negative allosteric ... [Published Zecco - May 01 2013]
First reported Apr 30 2013 - Updated May 01 2013 - 24 reports

Addex Reports that Dipragluant Demonstrated Dose-Dependent mGlu5 Receptor Occupancy in a Non-Human P

Addex Therapeutics / rimate PET Study.Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement. · Dose-dependent receptor occupancy correlates with plasma exposure and links to efficacy in ... [Published Interest!ALERT - May 01 2013]
First reported Apr 25 2013 - Updated Apr 25 2013 - 1 reports

Addex receives Netherlands regulatory approval to begin phase 1 study of ADX71441

The regulatory authorities in the Netherlands have approved the Addex Therapeutics' clinical trial application (CTA) to initiate a phase 1 study of ADX71441, a GABA-B receptor positive allosteric modulator (PAM). The company plans to initiate clinical ... [Published PharmaBiz - Apr 25 2013]
First reported Apr 22 2013 - Updated Apr 22 2013 - 7 reports

Addex Announces Issuance of a Broad European Composition; Di. . .

Addex Announces Issuance of a Broad European Composition; Dipraglurant, an mGlu5 negative allosteric modulator, in clinical development for levodopa-induced dyskinesia as well as certain rare dystoniasM2 CommunicationsGeneva, Switzerland - Addex Therapeutics ... [Published Equities.com - Apr 22 2013]
First reported Apr 19 2013 - Updated Apr 19 2013 - 1 reports

Dipraglurant data supports orphan disease focus

Apr 19th 2013 - today published a report on Addex Therapeutics entitled "Dipraglurant Data Supports Orphan Disease Focus". In summary, the report says:Positive preclinical data for dipraglurant in dystonia supports progression into a Phase II study for ... [Published Stockopedia - Apr 19 2013]
First reported Apr 18 2013 - Updated Apr 18 2013 - 8 reports

Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1) (Addex Therapeutics)

Addex Therapeutics /Addex Dipraglurant Normalizes Striatal Cholinergic Dysfunction in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1 (DYT1) . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for ... [Published Presscontacts.com - Apr 18 2013]

Quotes

...as a potential biomarker for an efficacy signal and fully supports its inclusion in our first-in-man program," stated Graham Dixon, CSO at Addex. "The use of growth hormone as a biomarker in the phase 1 will allow us to obtain early information about target engagement, guide dose selection for further clinical development and possibly provide us an understanding of the therapeutic potential of ADX71441."
Addex validates potential efficacy biomarker for phase 1 trial of GABA-B positive allosteric modu ... [Published PharmaBiz - May 22 2013]
...for the excellent job Tim has done and his loyalty and dedication to Addex over the past decade," said André J Mueller, Chairman of Addex. "We wish him continued success in his future endeavors. Thanks to Tim agreeing to a short-term external consulting role, Addex is assured of a seamless transition."
Addex Therapeutics Announces CFO, to Transition to External Consulting Role [Published BioSpace - May 01 2013]
...MNI vice-president chemistry and translational science Gilles Tamagnan said: "The results of the study are in line with previous reports on mGlu5 receptor occupancy studies and are consistent with the preclinical pharmacology data gathered so far with dipraglurant. "We look forward to the next phase of the study; investigating receptor occupancy in human volunteers and Parkinson's patients." Story provided by StockMarketWire.com"
Study reinforces dipraglurant data, says Addex [Published Stock Market Wire - May 01 2013]
"The granting of this patent continues to broaden the patent estate around our lead program," said Bharatt Chowrira, Ph D , CEO at Addex. "Specifically, composition of matter patents have now been granted for dipraglurant in all the major markets - the US, Europe and Japan. Our intellectual property estate continues to yield key patents protecting novel oral small molecules discovered utilizing our industry leading allosteric modulation technology platform. This new patent significantly enhances the value of our dipraglurant franchise and we look forward to advancing dipraglurant into Phase II for the treatment of certain rare dystonias in the coming months."
Addex Therapeutics receives European patent for dyskinesia drug [Published Zecco - May 01 2013]

More Content

All (88) | News (70) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (1) | Press Releases (14)
sort by: Date | Relevance
Addex validates potential efficacy biomarker fo... [Published PharmaBiz - May 22 2013]
ADX71441 on track for phase 1 testing, says Addex [Published MoneyAM - May 21 2013]
Addex Rises on Positive Rodent Experiment Resul... [Published BusinessWeek - May 21 2013]
Addex Validates Potential Efficacy Biomarker fo... [Published Malaycr.com - May 21 2013]
Addex Validates Potential Efficacy Biomarker fo... [Published AndhraNews.net - May 21 2013]
Addex Validates Potential Efficacy Biomarker fo... [Published Live-PR.com - May 21 2013]
Addex Therapeutics: Addex Validates Potential E... [Published FinanzNachrichten.de - May 21 2013]
Addex Validates Potential Efficacy Biomarker fo... [Published PR inside - May 21 2013]
Addex Therapeutics (ADXN) - Pharmaceuticals & H... [Published TransWorldNews - May 18 2013]
Addex Reports ADX71441 Reduces Alcohol Intake i... [Published HighBeam Research - May 15 2013]
Addex Therapeutics Announces CFO, to Transitio... [Published BioSpace - May 01 2013]
Study reinforces dipraglurant data, says Addex [Published Stock Market Wire - May 01 2013]
NXP Acquires Code Red Technologies [Published NewsBlaze - May 01 2013]
Addex Therapeutics receives European patent for... [Published Zecco - May 01 2013]
Addex Reports that Dipragluant Demonstrated Dos... [Published Interest!ALERT - May 01 2013]
Addex Reports that Dipragluant Demonstrated Dos... [Published Presscontacts.com - May 01 2013]
Addex Therapeutics : Addex Reports that Dipragl... [Published Investegate - May 01 2013]
Addex Reports that Dipragluant Demonstrated Dos... [Published Yahoo! Finance - May 01 2013]
Addex Reports that Dipragluant Demonstrated Dos... [Published Marketwire - Breaking News Releases - May 01 2013]
ADDEX PHARMACEUTICALS SA: Reports that Dipraglu... [Published 4 Traders - May 01 2013]
Addex Reports that Dipragluant Demonstrated Dos... [Published Saudi Fransi Capital - May 01 2013]
Addex Reports that Dipragluant Demonstrated Dos... [Published OSIX News - May 01 2013]
Addex Reports that Dipragluant Demonstrated Dos... [Published Best Invest - May 01 2013]
Addex Reports ADX71441 Reduces Alcohol Intake i... [Published PipelineReview - May 01 2013]
Addex Announces CFO, Tim Dyer, to Transition to... [Published Presscontacts.com - Apr 30 2013]
Addex Announces CFO, Tim Dyer, to Transition to... [Published Best Invest - Apr 30 2013]
Addex Announces CFO, Tim Dyer, to Transition to... [Published Yahoo! Finance - Apr 30 2013]
Addex Announces CFO, Tim Dyer, to Transition to... [Published Marketwire - Breaking News Releases - Apr 30 2013]
ADDEX PHARMACEUTICALS SA: Announces CFO, Tim Dy... [Published 4 Traders - Apr 30 2013]
Addex Announces CFO, Tim Dyer, to Transition to... [Published Scottrade - Apr 30 2013]
1 2 3
In Focus
  •  
Bharatt Chowrira, Graham Dixon, Andre J., [more]
  •  
Ortho-McNeil-Janssen Pharmaceuticals Inc, PAMs, A2A SpA, [more]
  •  
Michael J. Fox Foundation, European Patent Office, Tufts University, [more]
  •  
Receptor, Parkinson's Disease, Dyskinesia, [more]
  •  
Lentivector, Boeing 787, MoxDuo, [more]
  •  
Geneva, Rome, Plan-les-Ouates (Switzerland), [more]
  •  
Switzerland, United States, Japan, [more]
  •  
Diseases, Medication, Research & Development, [more]
  •  
IT, Utilities, Banking & Financial Services, [more]
Marketwire - Breaking News Releases, Presscontacts.com, Investegate, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Addex wins $1m Michael J Fox Foundation grant f... [Published PBR - News - Mar 20 2013]
Addex Therapeutics has won $1m grant from the Michael J Fox Foundation to support human clinical testing of dipraglurant against Parkinson's disease levodopa-induced dyskinesia (PD-LID). ...
Addex Cuts Back: An Old Story, Told Again [Published In the Pipeline - Feb 07 2013]
Addex Therapeutics has been trying to develop allosteric modulators as drugs. That's a worthy goal (albeit a tough one) - "allosteric" is a term that covers an awful lot of ground. The basic definition is a site that affects the activity of its protein, ...
Investment Research Weekly Roundup including Af... [Published Proactiveinvestors United Kingdom website - Dec 07 2012]
    Optimal Payments- LON:OPAY Flash note - Strengthening its position in the US 06 December 2012 Optimal Payments has signed an agreement to provide gateway services to Vantiv, a US provider of payment processing and related technology solutions. ...
1

Press Releases

sort by: Date | Relevance
Addex Validates Potential Efficacy Biomarker fo... [Published PR inside - May 21 2013]
Addex Reports that Dipragluant Demonstrated Dos... [Published Marketwire - Breaking News Releases - May 01 2013]
Addex Announces CFO, Tim Dyer, to Transition to... [Published Marketwire - Breaking News Releases - Apr 30 2013]
Addex Reports ADX71441 Reduces Alcohol Intake i... [Published Marketwire - Breaking News Releases - Apr 30 2013]
Addex Receives Approval to Initiate a Phase 1, ... [Published Marketwire - Breaking News Releases - Apr 24 2013]
1 2 3
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.